Vivoryon Therapeutics Faces Big Losses, Questions Its Future in Alzheimer & Cancer R&D
Vivoryon Therapeutics’ sharp decline, loss‑heavy P/E, and battle‑ridden focus on Alzheimer’s and oncology reveal a biotech company at a critical juncture, questioning its future sustainability.
2 minutes to read